| Trial ID: | L0933 |
| Source ID: | ISRCTN05474560
|
| Associated Drug: |
VSL#3
|
| Title: |
The impact of VSL#3 probiotic on cardiovascular risk and liver injury in patients with non alcoholic fatty liver disease: a randomised, double blinded, placebo controlled proof-of-concept trial
|
| Acronym: |
--
|
| Status: |
Not Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Diabetes Research Network, Oral and Gastrointestinal <br>Not Applicable
|
| Interventions: |
Two study visits per participant, randomised to receive either treatment or placebo on a 1:1 ratio. Treatment arm will take VSL#3 probiotic 2 sachets twice a day for 10 weeks. Placebo arm will take placebo 2 sachets twice a day for 10 weeks. Participants
|
| Outcome Measures: |
Cardiovascular biomarkers pre and post interventionLiver fat and inflammation - compare fibrosis risk score and structural liver changes before and after study intervention
|
| Sponsor/Collaborators: |
Portsmouth Hospitals NHS Trust (UK)
|
| Gender: |
All
|
| Age: |
nannan
|
| Phases: |
Not applicable
|
| Enrollment: |
60
|
| Study Type: |
Interventional
|
| Study Designs: |
Randomised interventional trial (Treatment)
|
| Start Date: |
09/08/2012
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
17 October 2016
|
| Locations: |
United Kingdom
|
| URL: |
http://isrctn.com/ISRCTN05474560
|
